Inhibrx Biosciences股价暴跌22%，缘于该公司披露了其试验性组合癌症药物的中期阶段研究数据。市场对此反应剧烈，股价应声大幅下挫。这家生物科技企业此番公布的数据，源于一项针对该联合疗法疗效和安全性的中段临床试验。投资者在审视这些最新出炉的结果后，显然对前景产生了疑虑，进而引发了抛售潮，拖累股价在交易时段内录得显著跌幅。
Inhibrx Biosciences股价暴跌22%，缘于该公司披露了其试验性组合癌症药物的中期阶段研究数据。市场对此反应剧烈，股价应声大幅下挫。这家生物科技企业此番公布的数据，源于一项针对该联合疗法疗效和安全性的中段临床试验。投资者在审视这些最新出炉的结果后，显然对前景产生了疑虑，进而引发了抛售潮，拖累股价在交易时段内录得显著跌幅。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.